Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibit
about
Class III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory AnalysisFLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?Advancing the Minimal Residual Disease Concept in Acute Myeloid LeukemiaPrognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemiaMolecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice.Prenatal origin of childhood AML occurs less frequently than in childhood ALL.Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemiaFLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia.A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes.The Biology and Targeting of FLT3 in Pediatric Leukemia.Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.The Future of Targeting FLT3 Activation in AML.Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotypeClofarabine for the treatment of adult acute myeloid leukemia.FLT3/ITD AML and the law of unintended consequences.Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.Determination of minimal residual disease in leukaemia patients.Flt3 mutations and leukaemia.FLT3: ITDoes matter in leukemia.Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid eraDasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.Internal tandem duplications of the FLT3 gene are present in leukemia stem cellsQuantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length.Acute myeloid leukemia stem cells and CD33-targeted immunotherapyBiology and management of relapsed acute myeloid leukaemia.Molecular genetic analysis of haematological malignancies: I. Acute leukaemias and myeloproliferative disorders.Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia.Comparative analysis of different approaches to measure treatment response in acute myeloid leukemiaAdult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group.The detection and significance of minimal residual disease in acute and chronic leukemia.Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia.Aberrant cytokine signaling in leukemia.Progress of minimal residual disease studies in childhood acute leukemia.Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.Minimal residual disease quantitation in acute myeloid leukemiaNovel targeted drug therapies for the treatment of childhood acute leukemia
P2860
Q26797245-2AEF8D99-6031-48FD-8543-B40B5FE9AB27Q27028163-ADF20197-B90C-41EA-B7D6-D51F73767D8FQ28087291-034E1864-A8AB-482B-8B3F-75823534E269Q28186429-B0B2E81B-0FB7-4C0F-A543-7F52B4F0997DQ30252938-D6666983-AEF6-482D-867F-E15FAC9109B3Q30300790-D17B8285-647D-46A0-A20D-E6995D04AD70Q33240663-C0DD96EF-4DDB-4736-ADCB-C42605A326BDQ33491557-21586834-CC5C-452C-A29F-787C4539942EQ33680292-C9559A10-C258-49D6-9824-A1569958F37BQ33704528-80A058B7-732D-4CBC-B9EF-BDAA7AF1F074Q33716570-3903BF77-B92B-4E3C-872A-F8324462D225Q34229555-A6691778-11AB-45AB-B2B7-8BE17CD7AB46Q34403931-DE8D4439-4384-44A8-B189-E9416041906AQ34555386-8F3F63A9-DC67-443F-8E4C-0B6B233EDA83Q34620761-2A773DCD-28FD-4BB5-8B95-22382CD07D3EQ34890418-90ED5DFA-2F7F-4695-A499-249EF7BC6DDFQ35009273-47C65A2A-C440-4010-A042-B78400249250Q35127958-5ACE87DE-1DCD-454B-AB20-04F19C17D3D6Q35134983-6934E134-56B9-4493-B7A9-F739C44CB34FQ35145184-9B585614-5FB4-467F-875B-FFC9EB59B09EQ35192266-FF4B0F2B-3D20-4622-A8A3-0DBF644E3040Q35217399-8D34AA30-7737-40BA-9234-3CCCAA785721Q35640734-2FB982DB-EDD1-48C6-8327-C57DA84F893BQ35669870-4DFE631D-14CC-48CD-8B47-F0E1DD72E757Q35750567-C1374BAB-4C73-4210-8573-CD9FF41A0D2AQ35847990-9CF4517F-0E34-4403-BBCE-8F5E0EC6A754Q36022521-E95A99C9-6239-4ED4-B0DE-8195EE434DD3Q36058588-8EA09FFF-0EDC-48C0-870C-818047DB2744Q36085026-0581251C-A49F-4FAD-B511-C094137EBD25Q36153422-D51544E5-337E-441A-BB1A-75FCC0A9F383Q36255287-83AD6BD4-2CD0-469C-AD8D-A2FE714CB1A3Q36290737-86008183-075D-445A-8699-728823E0B574Q36593525-16EB8142-21B8-4570-B246-DF92B66E85D1Q36648048-EAB03532-5DA7-4DDD-A04C-DBC51DB7EBD9Q36842838-F423DA62-2FB8-4C23-A302-1C669322FF33Q36970192-520A32E0-7E96-408C-9918-436BF510F30CQ36981845-FFC0D7AF-91EB-4528-8F17-12003C2F11A4Q37133515-95D73909-60DC-47EB-AE9F-ED3EBA09B1C3Q37447344-188918AB-9982-4D8F-9206-E2C2F6257778Q37477482-D6FA2A89-C755-4F74-BF38-30666B1C8ED0
P2860
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibit
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Studies of FLT3 mutations in p ...... ible therapy with FLT3 inhibit
@en
Studies of FLT3 mutations in p ...... ible therapy with FLT3 inhibit
@nl
type
label
Studies of FLT3 mutations in p ...... ible therapy with FLT3 inhibit
@en
Studies of FLT3 mutations in p ...... ible therapy with FLT3 inhibit
@nl
prefLabel
Studies of FLT3 mutations in p ...... ible therapy with FLT3 inhibit
@en
Studies of FLT3 mutations in p ...... ible therapy with FLT3 inhibit
@nl
P2093
P1433
P1476
Studies of FLT3 mutations in p ...... ible therapy with FLT3 inhibit
@en
P2093
David C Linch
David T Bowen
Marion E Frew
Panagiotis D Kottaridis
Rosemary E Gale
Stephen E Langabeer
P304
P356
10.1182/BLOOD-2002-02-0420
P407
P577
2002-10-01T00:00:00Z